DRD1 and Parkinson disease: The lead candidate DUSBI-A3 was highly selective for D1Rover closely related dopamine receptors when assessed by β-arrestinactivation, providing proof-of-concept for pursuing D1R selective,biased compounds in the treatment of PD.